Simponi, Cimzia REMS A Portent For Rest Of TNF Class
This article was originally published in Pharmaceutical Approvals Monthly
The Risk Evaluation and Mitigation Strategies for Centocor's Simponi and UCB's Cimzia offer a guide to how sponsors of other tumor necrosis factor inhibitors can be expected to educate physicians about the risk of invasive fungal infections, including histoplasmosis, associated with the class of medications.
You may also be interested in...
FDA is using its new drug safety authority to require label changes within 30 days for all four products in the tumor necrosis factor inhibitor class
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011